Aspira Women's Health Files 8-K on Agreements and Equity Sales
Ticker: AWHL · Form: 8-K · Filed: Sep 25, 2025 · CIK: 926617
Sentiment: neutral
Topics: material-definitive-agreement, equity-sale, financial-statements
TL;DR
Aspira Women's Health (AWH) filed an 8-K detailing new deals and stock sales.
AI Summary
Aspira Women's Health Inc. filed an 8-K on September 25, 2025, reporting on events that occurred on September 19, 2025. The filing indicates an entry into a material definitive agreement, unregistered sales of equity securities, and includes financial statements and exhibits. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware.
Why It Matters
This 8-K filing signals significant corporate actions, including new agreements and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves unregistered sales of equity securities and material definitive agreements, which can introduce financial and operational risks.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- September 19, 2025 (date) — Earliest event reported
- September 25, 2025 (date) — Date of report
- Vermillion, Inc. (company) — Former company name
- Ciphergen Biosystems Inc (company) — Former company name
- Abiotic Systems (company) — Former company name
FAQ
What type of material definitive agreement did Aspira Women's Health Inc. enter into?
The filing indicates an entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What was the date of the earliest event reported in this 8-K filing?
The earliest event reported was on September 19, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on September 25, 2025.
What are some of the former names of Aspira Women's Health Inc. mentioned in the filing?
The filing mentions former names including Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.
What are the main items reported in this 8-K filing?
The main items reported are entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 861 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2025-09-25 16:01:42
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 AWHL OTC QB Market Indicate by ch
- $1,370,000 — ") of an aggregate principal amount of $1,370,000 in the form of Senior Secured Convertib
- $0.25 — hich were exercisable for five years at $0.25 per share for the first 24 months after
- $0.50 — the first 24 months after issuance and $0.50 per share thereafter. As of the date he
- $0.35 — o provide for a fixed exercise price of $0.35 per share, eliminate the cashless exerc
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex4-1.htm (EX-4.1) — 138KB
- ex10-1.htm (EX-10.1) — 20KB
- 0001493152-25-014925.txt ( ) — 394KB
- awhl-20250919.xsd (EX-101.SCH) — 3KB
- awhl-20250919_lab.xml (EX-101.LAB) — 33KB
- awhl-20250919_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: September 25, 2025 ASPIRA WOMEN'S HEALTH INC. By: /s/ Michael Buhle Name: Michael Buhle Title: Chief Executive Officer